c-Myc and Cyclin D3 (CcnD3) Genes Are Independent Targets for Glucocorticoid Inhibition of Lymphoid Cell Proliferation

Cancer Research

Volumn 55, Issue 18, 1995, Pages 4188-4195

  Rhee, Kunsoo ^a,b   Bresnahan, Wade ^a   Hirai, Aki ^a,c   Hirai, Masashi ^a,c   Thompson, E Aubrey ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE TARGETING; GENETIC REGULATION; IMMUNE SYSTEM; LYMPHOID CELL; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL;

ANIMAL; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CELL DEATH; CELL DIVISION; CYCLINS; DRUG RESISTANCE; G0 PHASE; GENES, MYC; GLUCOCORTICOIDS; MICE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RETINOBLASTOMA PROTEIN; SIMIAN VIRUS 40; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0029161862     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Harmon, J. M., Norman, M. R., Fowlkes, B. J., and Thompson, E. B. Dexamethasone induces irreversible G1 arrest and death of a human lymphoid line. J. Cell. Physiol., 98:267–278, 1979.
2. Forsthoefel, A. M., and Thompson, E. A. Glucocorticoid regulation of transcription of the c-myc cellular proto-oncogene in PI798 cells. Mol. Endocrinol., 1:899–907, 1987.
3. Eastman-Reks, S. B., and Vedeckis, W. Glucocorticoid inhibition of c-myc and c-Ki-ras expression in a mouse lymphoma cell line. Cancer Res., 46:2457–2463, 1986.
4. Ma, T., Mahajan, P. B., and Thompson, E. A. Glucocorticoid regulation of c-myc promoter utilization in P1798 T-lymphoma cells. Mol. Endocrinol., 6:960–968, 1992.
5. Yu, Y. S., and Thompson, E. B. Glucocorticoid effect on oncogene/growth gene expression in human T lymphoblastic leukemia cell line CCRF-CEM. J. Biol. Chem., 264:10904–10910, 1989.
6. Thulasi, R., Harbour, D. V., and Thompson, E. B. Suppression of c-myc is a critical step in glucocorticoid-induced human leukemic cell lysis. J. Biol. Chem., 268:18306–18312, 1993.
7. Sherr, C. J. Mammalian G1 cyclins. Cell, 73:1059–1065, 1993.
8. Sherr, C. J. G1 phase progression:cycling on cue. Cell, 79:551–555, 1994.
9. Hunter, T., and Pines, J. Cyclins and cancer II:cyclin D and CDK inhibitors come of age. Cell, 79:573–582, 1994.
10. Draetta, G. Mammalian G1 cyclins. Curr. Opin. Cell. Biol., 6:842–846, 1994.
11. Kato, J. Y., Matsushime, H., Hiebert, S. W., Ewen, M. E., and Sherr, C. J. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev., 7:331–342, 1993.
12. Ewen, M. E., Sluss, H. K., Sherr, O. J., Matsushime, H., Kato, J.-Y., and Livingston, D. Functional interactions of the retinoblastoma protein with mammalian D type cyclins. Cell, 73:487–497, 1993.
13. Buchkovich, K., Duffy, L. A., and Harlow, E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell, 58:1097–1105, 1989.
14. DeCaprio, J. A., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C.-M., and Livingston, D. M. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell, 58:1085–1095, 1989.
15. Ludlow, J. W., DeCaprio, J. A., Huang, C. M., Lee, W. H., Paucha, E., and Livingston, D. M. SV40 large T antigen binds preferentially to an underphosphory-lated member of the retinoblastoma susceptibility gene product family. Cell, 56:57–65, 1989.
16. Baldin, V., Lukas, J., Marcote, M. J., Pagano, M., and Draetta, G. Cyclin Dl is a nuclear protein required for cell cycle progression in G. Genes Dev., 7; 812–821, 1993.
17. Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J.-Y., Bar-Sagi, D., Roussel, M. F., and Sherr, C. J. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev., 7:1559–1571, 1993.
18. Reed, S. I. Pheromone signaling pathways in yeast. Curr. Opin. Genet. Dev., 1:391–396, 1991.
19. Ewen, M. E., Sluss, H. K., Whitehouse, L. L., and Livingston, D. M. TGF0 inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell, 74:1009–1020, 1993.
20. Geng, Y., and Weinberg, R. A. Transforming growth factor 0 effects on expression of G1 cyclins and cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA, 90:10315–10319, 1993.
21. Ko, T. C., Sheng, H. M., Reisman, D., Thompson, E. A., and Beauchamp, R. D. Transforming growth factor-131 inhibits cyclin Dl expression in intestinal epithelial cells. Oncogene, 10:177–184, 1995.
22. Rhee, K., Reisman, D., Bresnahan, W., and Thompson, E. A. Glucocorticoid regulation of G1 cyclin-dependent kinase genes in lymphoid cells. Cell Growth & Differ., 6:691–698, 1995.
23. Nevins, J. R. A link between the RB tumor suppressor protein and viral oncoproteins. Science (Washington DC), 258:424–429, 1992.
24. Thompson, E. A. Insensitivity to the cytolytic effects of glucocorticoids in vivo is associated with a novel “slow death” phenotype. Cancer Res., 51:5544–5550, 1991.
25. Thompson, E. A. Glucocorticoid insensitivity of PI798 lymphoma cells is associated with production of a factor that attenuates the lytic response. Cancer Res., 51:5551–5556, 1991.
26. Thompson, E. A., Moore, W. M., and Sawyer, R. H. Glucocorticoid effects on lymphosarcoma PI798:DNA replication and growth of subcutaneous tumors in mice. J. Natl. Cancer Inst., 65:648–655, 1980.
27. Patterson, M. K., Jr. Measurement of growth and viability of cells in culture. Methods Enzymol., 58:141–151, 1979.
28. Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J., Hanks, S. K., Roussel, M. F., and Sherr, C. J. Identification and properties of an atypical catalytic subunit (p34PSK’ j3/cdk4) for mammalian D type G1 cyclins. Cell, 71:323–334, 1992.
29. Meyerson, M., and Harlow, E. Identification of Gj kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol., 14:2077–2086, 1994.
30. Rhee, K., Ma, T., and Thompson, E. A. The macromolecular state of the transcription factor E2F and glucocorticoid regulation of c-Myc transcription. J. Biol. Chem., 269:17039–17042, 1994.
31. Barbour, K. W., Berger, S. H., Berger, F. G., and Thompson, E. A. Glucocorticoid regulation of the genes encoding thymidine kinase, thymidylate synthase, and ornithine decarboxylase in P1798 cells. Mol. Endocrinol., 2:78–84, 1988.
32. Peter, M., and Herskowitz, I. Joining the complex:cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell, 79:181–184, 1994.
33. Elledge, S. J., and Harper, J. W. Cdk inhibitors:on the threshold of checkpoints and development. Curr. Opin. Cell Biol., 6:847–852, 1994.
34. Munck, A. Metabolic site and time course of Cortisol action on glucose uptake, lactic acid output and glucose-6-phosphate levels on rat thymus cells in vitro. J. Biol. Chem., 243:1039–1044, 1968.
35. Young, D. A., Voris, B. P., and Nicholson, M. L. Cellular and biochemical actions of adrenal glucocorticoid hormones on rat thymic lymphocytes. Environ. Health Per-spect., 38:89–97, 1981.
36. Siegel, R. M., Katsumata, M., Miyashita, T., Louie, D. C., Greene, M. I., and Reed, J. C. Inhibition of thymocyte apoptosis and negative antigenic selection in bcl-2 transgenic mice. Proc. Natl. Acad. Sci. USA, 89:7003–7007, 1992.